Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: L01CE01

Evotopin(topotecan)

Ovarian Neoplasms

Marketing Authorisation Holder: Beecham Group plc

EMA Authorisation: 15/04/1997

INN: topotecan

Indication

Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Evotopin — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.